Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Completes $4.5 Billion Stock Buyback Ahead of Schedule

NEW YORK, June 22 (GenomeWeb News) - Agilent Technologies has completed its $4.5 billion stock repurchase program ahead of schedule, the company said today.


Agilent acquired approximately 125 million shares of its common stock under the program. Agilent expects to report approximately 430 million average shares outstanding on a fully diluted basis during its third quarter ending July 30.


Agilent's board of directors authorized the buyback program on Aug. 15, 2005, along with the sale of its semiconductor-related business. The buyback was projected to complete by the end of this year.


The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.